Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
By endorsing Mark Cuban's proposals to make prescription drug pricing more transparent, Bill Ackmanshifted the conversation from healthcare policy to something investors care about just as much: whether the traditional pharmacy benefit manager (PBM) model is facing a growing structural challenge.
Cuban's proposals center on allowing patients to buy lower-priced cash prescriptions without losing insurance benefits, standardizing PBM contracts, making pricing economics public, eliminating contractual "gag clauses," and strengthening enforcement against repeat offenders.
Don't Miss:
-
Think Your 'Safe' Stocks Protect You? You're Ignoring the Real Growth Triggers — Here's What to Add Now
-
Caught With Nothing Saved for Retirement? These 5 Game‑Changing Tips Could Still Save You
The proposals are closely aligned with the philosophy behind Mark Cuban Cost Plus Drug Company, which bypasses traditional PBMs and sells medicines using a publicly disclosed pricing formula: the wholesale acquisition cost, plus a 15% markup, a pharmacy fee, and shipping.
The model aims to eliminate "spread pricing," where PBMs can profit from the difference between what they pay for drugs and what health plans reimburse.
. @mcuban is totally right about this approach to reducing drug prices. https://t.co/DWR0JTM1Qz
— Bill Ackman (@BillAckman) September 2, 2026
Trending: Think you're saving enough for your kids? You might be dangerously off — see why
Which Healthcare Stocks Could Benefit?
The significance for investors lies less in Cost Plus Drugs itself—which is privately held—and more in which public companies are adapting to this shift:
-
Humana Inc.stands out because it has worked with Cost Plus Drugs through SwiftyRxto steer members toward lower-cost prescription options. If employers and state governments increasingly embrace transparent pricing models, insurers that incorporate lower-cost pharmacy solutions could benefit from reduced drug spending while differentiating themselves in a competitive Medicare Advantage market.
-
CVS Health Corp, The Cigna Group's Express Scripts and UnitedHealth Group Inc's Optum Rx have long relied on managing drug benefits, negotiating rebates and administering pharmacy networks.
Greater transparency around pricing, rebates and contracts could put pressure on some of those economics over time, particularly as lawmakers continue pushing for additional disclosure requirements.
Many of Cuban's recommendations echo reforms already under consideration in Washington. The Department of Labor's proposed PBM transparency rule would require disclosure of rebates, spread-pricing income and other compensation, reflecting a broader push to make prescription drug pricing less opaque.
See Also: Still Learning the Market? These 50 Must-Know Terms Can Help You Catch Up Fast
Watch the Trend, Not the Tweet
Ackman's endorsement alone is unlikely to reshape the healthcare industry. But it adds another influential voice to a growing push for simpler and more transparent drug pricing—a trend that has gained traction among entrepreneurs, policymakers and regulators alike.
For investors, the bigger takeaway is to watch where healthcare profits migrate if that trend accelerates. Companies that help lower prescription costs through transparent distribution models may find new growth opportunities, while businesses whose earnings depend on opaque pricing and rebate structures could face mounting pressure.
The investment question is no longer whether drug pricing reform is being discussed; it's which companies are positioned for a healthcare system where transparency becomes a competitive advantage.
Image via Shutterstock
Building Wealth Across More Than Just the Market
Building a resilient portfolio means thinking beyond a single asset or market trend. Economic cycles shift, sectors rise and fall, and no one investment performs well in every environment. That's why many investors look to diversify with platforms that provide access to real estate, fixed-income opportunities, precious metals, and even self-directed retirement accounts. By spreading exposure across multiple asset classes, it becomes easier to manage risk, capture steady returns, and create long-term wealth that isn't tied to the fortunes of just one company or industry.
Arrived
Backed by Jeff Bezos, Arrived Homes makes real estate investing accessible with a low barrier to entry. Investors can buy fractional shares of single-family rentals and vacation homes starting with as little as $100 . This allows everyday investors to diversify into real estate, collect rental income, and build long-term wealth without needing to manage properties directly.
Qnetic
As electricity demand rises alongside AI, data centers, and renewable energy, long-duration energy storage is becoming increasingly important. Qnetic is developing a kinetic energy storage system designed to provide long-lasting, chemical-free electricity storage , offering investors exposure to the infrastructure supporting a more resilient and reliable power grid.
EquityMultiple
For accredited investors looking beyond stocks and bonds, EquityMultiple provides access to vetted commercial real estate deals starting at $5,000 , with only ~5% of opportunities passing their due diligence process.
FarmTogether
Farmland has historically held its value through market volatility and delivered returns uncorrelated to stocks and bonds. For accredited investors, FarmTogether offers direct access to high-quality U.S. farmland starting at $15,000 — fully managed, with no landlord headaches.
Fundrise
Private real estate and private credit can add income and stability to a stock-heavy portfolio. Fundrise offers access to diversified private real estate and credit strategies through an easy-to-use platform, with professionally managed portfolios designed to generate passive income and long-term growth.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
